Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹11,001 Cr
Revenue (TTM)
₹2,623 Cr
Net Profit (TTM)
₹381 Cr
ROE
16.5 %
ROCE
22.4 %
P/E Ratio
28.9
P/B Ratio
4.5
Industry P/E
--
EV/EBITDA
17.2
Div. Yield
0.3 %
Debt to Equity
0
Book Value
₹54.4
EPS
₹8.4
Face value
1
Shares outstanding
453,163,746
CFO
₹1,255.85 Cr
EBITDA
₹2,140.33 Cr
Net Profit
₹1,448.60 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Marksans Pharma
| -18.2 | -1.6 | 12.0 | 49.2 | 81.4 | 45.4 | 14.5 |
|
BSE Healthcare
| -4.5 | 1.4 | 2.4 | 17.2 | 26.0 | 20.7 | 10.2 |
|
BSE Small Cap
| -3.2 | 3.0 | 12.2 | 2.1 | 30.0 | 33.2 | 16.9 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Marksans Pharma
| 84.7 | 176.6 | -3.2 | -1.3 | 253.6 | -40.8 | -30.3 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Marksans Pharma
|
242.8 | 11,000.6 | 2,622.8 | 382.6 | 17.0 | 16 | 28.9 | 4.5 |
| 243.3 | 3,784.0 | 2,711.5 | 3.2 | 6.5 | 0.5 | -- | 0.6 | |
| 51.9 | 15.8 | 0.8 | 0.4 | 50.5 | 9 | 44.6 | 4.1 | |
| 575.0 | 13,805.1 | 2,839.3 | 406.7 | 16.0 | 20.5 | 33.9 | 5.4 | |
| 113.6 | 404.7 | 138.5 | 7.9 | 8.1 | 7.9 | 50.5 | 3.9 | |
| 29.8 | 895.8 | 1,006.4 | 46.5 | 8.0 | 11 | 19.3 | 2.0 | |
| 5,000.5 | 11,497.9 | 667.6 | 168.3 | 37.0 | 82.8 | 68.3 | 35.7 | |
| 8.5 | 125.9 | 0.0 | 37.5 | -- | -- | 3.4 | 6.1 | |
| 36.9 | 70.5 | 46.7 | 7.3 | 24.6 | 10.6 | 9.7 | 0.9 |
No Review & Analysis are available.
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic... hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India. Read more
Incorporated
1992
Chairman
Mark Saldanha
Managing Director
Mark Saldanha
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Marksans Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Marksans Pharma Ltd stood at ₹ 3,240 Cr as on 31-Mar-25
The share price of Marksans Pharma Ltd is ₹242.80 (NSE) and ₹242.75 (BSE) as of 24-Jun-2025 IST. Marksans Pharma Ltd has given a return of 81.44% in the last 3 years.
Marksans Pharma Ltd has a market capitalisation of ₹ 11,001 Cr as on 24-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Marksans Pharma Ltd is 4.46 times as on 24-Jun-2025, a 937% premium to its peers’ median range of 0.43 times.
The P/E ratio of Marksans Pharma Ltd is 28.91 times as on 24-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Marksans Pharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Marksans Pharma Ltd.
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
The promoter of Marksans Pharma Ltd is MARK SALDANHA. MARK SALDANHA owns 43.8 per cent of the total equity. The chairman of the company is Mark Saldanha , and the managing director is Mark Saldanha..
There is no promoter pledging in Marksans Pharma Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
11,689
|
|
|
3,816
|
|
|
902
|
|
|
406
|
|
|
123
|
|
|
71
|
|
|
15
|
|
|
13,842
|
| Marksans Pharma Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
16.03
|
|
Operating margin(%)
|
16.98
|
|
Net Margin(%)
|
14.21
|
|
Dividend yield(%)
|
0.33
|
Yes, TTM profit after tax of Marksans Pharma Ltd was ₹381 Cr.
₹2.10
(
